• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Prospects and progress in cell therapy for acute respiratory distress syndrome
【24h】

Prospects and progress in cell therapy for acute respiratory distress syndrome

机译：细胞治疗急性呼吸窘迫综合征的前景与进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Despite progress in understanding the pathophysiology of the acute respiratory distress syndrome (ARDS), it remains a devastating clinical disorder associated with high mortality rates, and those who survive can experience significant long-term morbidity. Recent advances in the management of ARDS have mostly been achieved in supportive care, including the use of protective mechanical ventilation, neuromuscular blocking agents, prone positioning, and conservative fluid strategies. However, to date, no pharmacologic therapy has been able to act effectively on disease-specific pathways or to reduce mortality. In this context, current advances in understanding the potential roles of alternative approaches, such as cell therapy, offer new hope for ARDS.Areas covered: This review discusses the use of mesenchymal stromal (stem) cells (MSCs) in pre-clinical experimental models of ARDS and in ongoing clinical trials.Expert opinion: Through the secretion of soluble mediators and extracellular vesicles, MSCs have been shown to modulate inflammation, enhance bacterial clearance, and reduce organ injury and death, making them a potential novel treatment for ARDS. Initial clinical trials have demonstrated the safety of MSC administration in patients with ARDS but further investigations are required to further characterize the efficacy profile of these therapies.
机译：简介：尽管在了解急性呼吸窘迫综合征（ARDS）的病理生理学方面取得了进展，但它仍然是与高死亡率相关的毁灭性临床疾病，并且存活下来的人可能会经历严重的长期发病。在支持性护理中，ARDS的管理方面的最新进展已获得很大支持，包括使用保护性机械通气，神经肌肉阻滞剂，俯卧位和保守性输液策略。然而，迄今为止，还没有药物疗法能够有效地针对疾病的特异性途径或降低死亡率。在这种情况下，目前了解细胞疗法等替代方法的潜在作用的新进展为ARDS带来了新的希望。研究领域：本综述讨论了间质基质细胞在临床前实验模型中的使用专家意见：通过分泌可溶性介质和细胞外囊泡，MSC已被证明可调节炎症，增强细菌清除率并减少器官损伤和死亡，使其成为ARDS的潜在新疗法。最初的临床试验证明了MSC在ARDS患者中的安全性，但需要进一步研究以进一步表征这些疗法的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号